897 related articles for article (PubMed ID: 33305988)
1. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
[TBL] [Abstract][Full Text] [Related]
2. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
3. Natural compounds from
Kar P; Sharma NR; Singh B; Sen A; Roy A
J Biomol Struct Dyn; 2021 Aug; 39(13):4774-4785. PubMed ID: 32552595
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of phytoconstituents of
Choudhary P; Singh T; Amod A; Singh S
J Biomol Struct Dyn; 2023 Jun; 41(9):4106-4123. PubMed ID: 35467486
[TBL] [Abstract][Full Text] [Related]
5. Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus
Abouelela ME; Assaf HK; Abdelhamid RA; Elkhyat ES; Sayed AM; Oszako T; Belbahri L; El Zowalaty AE; Abdelkader MSA
Molecules; 2021 Mar; 26(6):. PubMed ID: 33801151
[TBL] [Abstract][Full Text] [Related]
6. Cyanobacterial metabolites as promising drug leads against the M
Naidoo D; Roy A; Kar P; Mutanda T; Anandraj A
J Biomol Struct Dyn; 2021 Oct; 39(16):6218-6230. PubMed ID: 32691680
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
8. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
[TBL] [Abstract][Full Text] [Related]
9. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
10. Biflavonoids from
Lokhande K; Nawani N; K Venkateswara S; Pawar S
J Biomol Struct Dyn; 2022 Jul; 40(10):4376-4388. PubMed ID: 33300454
[TBL] [Abstract][Full Text] [Related]
11. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
12. Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, M
Naidoo D; Kar P; Roy A; Mutanda T; Bwapwa J; Sen A; Anandraj A
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500548
[TBL] [Abstract][Full Text] [Related]
13. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Therapeutic Potential of
Ali MA; Sheikh H; Yaseen M; Faruqe MO; Ullah I; Kumar N; Bhat MA; Mollah MNH
Molecules; 2024 May; 29(11):. PubMed ID: 38893400
[TBL] [Abstract][Full Text] [Related]
15. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
Dhankhar P; Dalal V; Kumar V
J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
[TBL] [Abstract][Full Text] [Related]
16. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
[TBL] [Abstract][Full Text] [Related]
17. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
[TBL] [Abstract][Full Text] [Related]
18. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19.
Rafi MO; Bhattacharje G; Al-Khafaji K; Taskin-Tok T; Alfasane MA; Das AK; Parvez MAK; Rahman MS
J Biomol Struct Dyn; 2022 May; 40(8):3711-3730. PubMed ID: 33251975
[TBL] [Abstract][Full Text] [Related]
19.
Philippsen GS; Seixas FAV
J Biomol Struct Dyn; 2024 Aug; 42(12):6440-6447. PubMed ID: 37424215
[TBL] [Abstract][Full Text] [Related]
20. In-silico guided design, screening, and molecular dynamic simulation studies for the identification of potential SARS-CoV-2 main protease inhibitors for the targeted treatment of COVID-19.
Gutti G; He Y; Coldren WH; Lalisse RF; Border SE; Hadad CM; McElroy CA; Ekici ÖD
J Biomol Struct Dyn; 2024; 42(4):1733-1750. PubMed ID: 37114441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]